David Mankoff
Professor University of Pennsylvania
Seminars
Astatine-211 offers significant advantages for smaller organic molecules due to its similarity to iodine in chemistry, eliminating the need for a chelator. This makes it easier to attach to drug-like molecules without altering their ability to bind to targets, unlike metal-based conjugates that often face challenges with chelator incorporation. While the supply of astatine is theoretically unlimited, niche cyclotron technologies affect availability.
Join this workshop for the opportunity to:
- Explore 211At decay properties to overcome toxicities
- Unlocking 211At conjugation chemistry and assessing prime biological targeting vectors, strategies, and targets
- Investigating potential of astatine development to industry-sponsored clinical trials
• Outlining At-211 labelled PARP-inhibitor analogs to target a binding site located on DNA
• Subcellar targeting to tumor DNA yield high potency alpha RPT
• Preclinical data support efficacy and tolerable toxicity in challenging disease such as neuroblastoma and ovarian cancer
